Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness

Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech division fell short of expectations.

JNJ (NYSE:JNJ), the